Effects of alendronate and interferon-γ on bone cancer cells in vitro

References

• Beresford, J. N., Taylor, G. T., & Teiffitt, J. T. (1990). Interferons and bone. The FEBS Journal, 193(2), 589–597. doi:10.1111/j.1432-1033.1990.tb19377.x
   Google Scholar
• Bukowski, J. F., Dascher, C. C., & Das, H. (2005). Alternative bisphosphonate targets and mechanisms of action. Biochemical and Biophysical Research Communications, 328(3), 746–750. doi:10.1016/j.bbrc.2004.11.075
   PubMed Web of Science ®Google Scholar
• Cornelis, F., Truchetet, M. E., Amoretti, N., Verdier, D., Fournier, C., Pillet, O., … Hauger, O. (2014). Bisphosphonate therapy for unresectable symptomatic benign bone tumors: A long-term prospective study of tolerance and efficacy. Bone, 58, 11–16. doi:10.1016/j.bone.2013.10.004
   PubMed Web of Science ®Google Scholar
• Cote, G. M. (2015). Rank ligand as a target in musculoskeletal neoplasms. Current Reviews in Musculoskeletal Medicine, 8(4), 339–343. doi:10.1007/s12178-015-9310-y
   PubMed Web of Science ®Google Scholar
• Dieli, F., Gebbia, N., Poccia, F., Caccamo, N., Montesano, C., Fulfaro, F., … Sireci, G. (2003). Induction of γδ T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood, 102(6), 2310–2311. doi:10.1182/blood-2003-05-1655
   PubMed Web of Science ®Google Scholar
• Fotakis, G., & Timbrell, J. A. (2006). In vitro cytotoxicity assays: Comparison of LDH, neutral red, MTT and protein assay in hepatoma cell lines following exposure to cadmium chloride. Toxicology Letters, 160(2), 171–177. doi:10.1016/j.toxlet.2005.07.001
   PubMed Web of Science ®Google Scholar
• Fournier, P. G., Chirgwin, J. M., & Guise, T. A. (2006). New insights into the role of T cells in the vicious cycle of bone metastases. Current Opinion in Rheumatology, 18(4), 396–404. doi:10.1097/01.bor.0000231909.35043.da
   PubMed Web of Science ®Google Scholar
• Gao, Y., Yang, W., Pan, M., Scully, E., Girardi, M., Augenlicht, L. H., … Yin, Z. (2003). γδ T cells provide an early source of interferon γ in tumor immunity. Journal of Experimental Medicine, 198(3), 433–442. doi:10.1084/jem.20030584
   PubMed Web of Science ®Google Scholar
• Giger, E. V., Castagner, B., & Leroux, J. C. (2013). Biomedical applications of bisphosphonates. Journal of Controlled Release, 167(2), 175–188. doi:10.1016/j.jconrel.2013.01.032
   PubMed Web of Science ®Google Scholar
• Goblirsch, M. J., Zwolak, P., & Clohisy, D. R. (2005). Advances in understanding bone cancer pain. Journal of Cellular Biochemistry, 96(4), 682–688. doi:10.1002/jcb.20589
   PubMed Web of Science ®Google Scholar
• Goldsby, R. E., Fan, T. M., Villaluna, D., Wagner, L. M., Isakoff, M. S., Meyer, J., … Gorlick, R. (2013). Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: A report from the Children’s Oncology Group. European Journal of Cancer, 49(10), 2384–2391. doi:10.1016/j.ejca.2013.03.018
   PubMed Web of Science ®Google Scholar
• Hofstaetter, J. G., Roschger, A., Puchner, S. E., Dominkus, M., Sulzbacher, I., Windhager, R., … Roschger, P. (2013). Altered matrix mineralization in a case of a sclerosing osteosarcoma. Bone, 53(2), 409–413. doi:10.1016/j.bone.2012.12.043
   PubMed Web of Science ®Google Scholar
• Huang, K. C., Cheng, C. C., Chuang, P. Y., & Yang, T. Y. (2015). The effects of zoledronate on the survival and function of human osteoblast-like cells. BMC Musculoskeletal Disorders, 16(1), 355. doi:10.1186/s12891-015-0818-5
   PubMedGoogle Scholar
• Im, G. I., Qureshi, S. A., Kenney, J., Rubash, H. E., & Shanbhag, A. S. (2004). Osteoblast proliferation and maturation by bisphosphonates. Biomaterials, 25(18), 4105–4115. doi:10.1016/j.biomaterials.2003.11.024
   PubMed Web of Science ®Google Scholar
• Kabelitz, D., Wesch, D., & He, W. (2007). Perspectives of γδ T cells in tumor immunology. Cancer Research, 67(1), 5–8. doi:10.1158/0008-5472.CAN-06-3069
   PubMed Web of Science ®Google Scholar
• Kansara, M., Teng, M. W., Smyth, M. J., & Thomas, D. M. (2014). Translational biology of osteosarcoma. Nature reviews. Cancer, 14(11), 722. doi:10.1038/nrc3838
   PubMed Web of Science ®Google Scholar
• Kobayashi, A., Hirano, F., & Makino, I. (2005). The inhibitory effect of bisphosphonates on glucocorticoid-induced RANKL expression in human cells. Scandinavian Journal of Rheumatology, 34(6), 480–484. doi:10.1080/03009740510026788
   PubMed Web of Science ®Google Scholar
• Kotake, S., Nanke, Y., Mogi, M., Kawamoto, M., Furuya, T., Yago, T., … Kamatani, N. (2005). IFN-γ-producing human T cells directly induce osteoclastogenesis from human monocytes via the expression of RANKL. European Journal of Immunology, 35(11), 3353–3363. doi:10.1002/eji.200526141
   PubMed Web of Science ®Google Scholar
• Kunzmann, V., Bauer, E., Feurle, J., Weißinger, F., Tony, H. P., & Wilhelm, M. (2000). Stimulation of γδ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood, 96(2), 384–392. Retrieved from http://www.bloodjournal.org/content/96/2/384
   PubMed Web of Science ®Google Scholar
• Lee, J. A., Jung, J. S., Kim, D. H., Lim, J. S., Kim, M. S., Kong, C. B., … Koh, J. S. (2011). RANKL expression is related to treatment outcome of patients with localized, high-grade osteosarcoma. Pediatric Blood & Cancer, 56(5), 738–743. doi:10.1002/pbc.22720
   PubMed Web of Science ®Google Scholar
• Li, Z., Peng, H., Xu, Q., & Ye, Z. (2012). Sensitization of human osteosarcoma cells to Vγ9 Vδ2 T-cell-mediated cytotoxicity by zoledronate. Journal of Orthopaedic Research, 30(5), 824–830. doi:10.1002/jor.21579
   PubMed Web of Science ®Google Scholar
• Lopes-Júnior, L. C., Silveira, D. S. C., Vulczak, A., dos Santos, J. C., Veronez, L. C., Fisch, A., … Pereira-da-Silva, G. (2016). Emerging cytokine networks in osteosarcoma. Oncology Communications, 2. doi:10.14800/oc.1167
   Google Scholar
• Lu, Y., Cai, Z., Xiao, G., Keller, E. T., Mizokami, A., Yao, Z., … Zhang, J. (2007). Monocyte chemotactic protein-1 mediates prostate cancer–induced bone resorption. Cancer Research, 67(8), 3646–3653. doi:10.1158/0008-5472.CAN-06-1210
   PubMed Web of Science ®Google Scholar
• Mariani, S., Muraro, M., Pantaleoni, F., Fiore, F., Nuschak, B., Peola, S., … Bruno, B. (2005). Effector γδ T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. Leukemia, 19(4), 664–670. doi:10.1038/sj.leu.2403693
   PubMed Web of Science ®Google Scholar
• Mirabello, L., Troisi, R. J., & Savage, S. A. (2009). Osteosarcoma incidence and survival rates from 1973 to 2004. Cancer, 115(7), 1531–1543. doi:10.1002/cncr.24121
   PubMed Web of Science ®Google Scholar
• Nannuru, K. C., & Singh, R. K. (2010). Tumor-stromal interactions in bone metastasis. Current Osteoporosis Reports, 8(2), 105–113. doi:10.1007/s11914-010-0011-6
   PubMedGoogle Scholar
• Ohba, T., Cole, H. A., Cates, J. M., Slosky, D. A., Haro, H., Ando, T., … Schoenecker, J. G. (2014). Bisphosphonates inhibit osteosarcoma-mediated osteolysis via attenuation of tumor expression of MCP-1 and RANKL. Journal of Bone and Mineral Research, 29(6), 1431–1445. doi:10.1002/jbmr.2182
   PubMed Web of Science ®Google Scholar
• Pan, B., Farrugia, A. N., To, L. B., Findlay, D. M., Green, J., Lynch, K., & Zannettino, A. C. (2004). The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-α converting enzyme (TACE). Journal of Bone and Mineral Research, 19(1), 147–154. doi:10.1359/jbmr.2004.19.1.147
   PubMed Web of Science ®Google Scholar
• Sato, K., Kimura, S., Segawa, H., Yokota, A., Matsumoto, S., Kuroda, J., … Maekawa, T. (2005). Cytotoxic effects of γδ T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy. International Journal of Cancer, 116(1), 94–99. doi:10.1002/ijc.20987
   PubMed Web of Science ®Google Scholar
• Sato, K., Suematsu, A., Okamoto, K., Yamaguchi, A., Morishita, Y., Kadono, Y., … Cua, D. J. (2006). Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. Journal of Experimental Medicine, 203(12), 2673–2682. doi:10.1084/jem.20061775
   PubMed Web of Science ®Google Scholar
• Takayanagi, H. (2000). T-cell-mediated regulation of osteoclastogenesis by signaling cross-talk between RANKL and IFN-γ. Nature, 408, 535–600. doi:10.1038/35046102
   PubMed Web of Science ®Google Scholar
• Van Poznak, C. H., Temin, S., Yee, G. C., Janjan, N. A., Barlow, W. E., Biermann, J. S., … Zuckerman, D. S. (2011). American society of clinical oncology executive summary of the clinical ancepractice guideline update on the role of bone-modifying agents in metastatic breast cr. Journal of Clinical Oncology, 29(9), 1221–1227. doi:10.1200/JCO.2010.32.5209
   PubMed Web of Science ®Google Scholar
• Zhu, Z. Q., Tang, J. S., Gang, D., Wang, M. X., Wang, J. Q., Lei, Z., … Yan, L. (2015). Antibody microarray profiling of osteosarcoma cell serum for identifying potential biomarkers. Molecular Medicine Reports, 12(1), 1157–1162. doi:10.3892/mmr.2015.3535
   PubMed Web of Science ®Google Scholar